Pliant Therapeutics Announces Interim Phase 1 Data Fro First Three Of Five Potential Cohorts Of Phase 1 Dose Escalation Trial Of PLN-101095; Says Antitumor Activity Observed With Confirmed Partial Responses In 50% Of Patients
Author: Benzinga Newsdesk | March 17, 2025 08:08am